Robust pre‑clinical support — performed in the U.S. and replicated in Europe

Our pre‑clinical services are performed by VisMederi America, based in the United States, providing integrated in vivo testing to support vaccine and biologics development programs. The same service portfolio can also be delivered by VisMederi, based in Italy, ensuring continuity, flexibility, and scalable support across geographies. Our pre-clinical testing capabilities include validated immunogenicity and neutralization assays such as ELISA, Luminex, HAI, ELLA, PBMC isolation, and live‑virus neutralization for pathogens including influenza, RSV, SARS‑CoV‑2, Human Metapneumovirus, Mpox, and others. For emerging and high‑risk viruses—such as Nipah, Lassa, Chikungunya, Ebola, Marburg, and MERS‑CoV—we offer pseudotyped‑virus microneutralization approaches that enable safe and informative immune assessment. By integrating in vivo models with downstream bioanalytical and virological analyses, we generate consistent, high‑quality data that supports candidate selection, dose optimization, and confident progression of pre‑clinical programs.